Wockhardt Ltd
Wockhardt Q2 FY25 earnings call: Revenue & Margins
Q2 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹809Cr
- +7.4% YoY
- Net profit
- −₹16Cr
- Q2 FY24: −₹73 Cr
- Margin
- 14%
- +4 pp YoY
Guidance rank: #17 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Wockhardt Ltd Q2 FY25 key numbers
- Revenue
- FY24 total income was INR 2,879 Cr., up 7% over FY23 (INR 2,693 Cr.).
As stated in Wockhardt Ltd's Q2 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Wockhardt Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Q1 FY25 EBITDA: INR 213 Cr., representing a 143% year-on-year growth vs Q1 FY24 (Page 12).
From Wockhardt Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. (Page 10)
- Quarterly EBITDA for Q1 FY25 was INR 100 Cr., a 213% growth year-on-year versus Q1 FY24 EBITDA of INR 32 Cr. (Page 12)
- FY24 total income was INR 2,879 Cr., up 7% over FY23 (INR 2,693 Cr.) (Page 10)
- FY24 EBITDA was INR 251 Cr., a 76% growth over FY23 (INR 143 Cr.) (Page 12)
Profitability & Margins
See what Wockhardt Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points from Wockhardt Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Wockhardt Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Wockhardt Ltd said on order book & pipeline — free account, 30 seconds.
Wockhardt Ltd — Quarterly revenue & net profit
Wockhardt Ltd Q2 FY25 results — key figures
| ₹ Cr | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 809 | 753 | +7.4% | 739 | +9.5% |
| Operating profit (EBITDA) | 110 | 72 | +52.8% | 91 | +20.9% |
| Operating margin | 14% | 10% | +4 pp | 12% | +2 pp |
| Profit before tax | -9 | -35 | — | -6 | — |
| Net profit (PAT) | -16 | -73 | — | -16 | — |
| EPS (₹) | -1.43 | -5.34 | — | -0.91 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹969 Cr, net profit ₹73 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Wockhardt's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY24 earnings call analysis →
- Q3 FY23 earnings call →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Jubilant Pharmo (Q2 FY25)
Q2’FY25 total income grew 5% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Anuh Pharma (Q2 FY25)
Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key concall takeaways from Anuh Pharma Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Themis Medicare (Q2 FY25)
117.01 Cr, up 11.67% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Wockhardt Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Wockhardt Ltd Q2 FY25 results?
Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Q1 FY25 EBITDA: INR 213 Cr., representing a 143% year-on-year growth vs Q1 FY24 (Page 12).
What is Wockhardt Ltd share price analysis?
Wockhardt Ltd currently shows a neutral. The stock trades at a P/E of 85.0 with a market cap of ₹33,897 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Wockhardt Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.